Drugs targeting the beta2-adrenoreceptor linked to Parkinson's disease
3 institutional releases
Published in Science · View the paper (DOI)
A new pathway to target Parkinson's disease has been identified, leveraging beta2-adrenergic agonists that lower alpha-synuclein production. Studies in mice and human health records suggest a 34% reduced PD risk for patients taking salbutamol.
Coverage from 3 institutions
- Drugs targeting the beta2-adrenoreceptor linked to Parkinson's disease Brigham and Women's Hospital · Aug 31, 2017 · first to report
- Compound regulates genetic risk factor in Parkinson's disease American Association for the Advancement of Science (AAAS) · Aug 31, 2017
- Asthma medicine halves risk of Parkinson's The University of Bergen · Aug 31, 2017